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C1-like 1 (NPC1L1) transporter is most likely responsible for the
transport of cholesterol and plant sterols from the brush border mem-
brane into the intestinal mucosa (6). The intestinal absorption of plant
sterols differs markedly from that of cholesterol and their biliary excretion
as well. The presence of two specific ABCG5/ABCG8 transporters in
the intestinal wall is responsible for rapid resecretion of plant sterols into
the intestine lumen and thus rather low intestinal absorption of campes-
terol and sitosterol, and their presence in the liver explains why plant
sterols are excreted much faster in the bile than cholesterol (7,8).
Ezetimibe interferes with NPC1L1, reducing the intestinal uptake of
cholesterol and plant sterols (6–8). Interestingly, the reduction of plant
sterol serum levels with ezetimibe was significantly more pronounced
than the reduction of serum cholesterol (7,8). Clinical data on ezetimibe
could demonstrate that the concept of inhibiting intestinal absorption of
neutral sterols is beneficial in both patients with hypercholesterolemia as
well in patients with hypersitosterolemia, an inherited disease with
identified mutations in ABCG5/ABCG8 transporters that leads to a
high prevalence of cardiovascular disease (9). Recent observations, such as
those by Miettinen et al. (1), that elevated serum plant sterols pose an
increased cardiovascular risk suggest that increases of serum plant sterol
levels should be avoided, especially in atherosclerosis-prone individuals
(1). Therefore, subjects with high cholesterol absorption and low synthe-
sis may need a therapy combining statin and ezetimibe to lower more
effectively their serum cholesterol levels and prevent an increase in the
levels of plant sterols (3). The question remains, however, as to whether
lowering serum levels of plant sterols (especially in high-absorber patients
on statin therapy) with a drug such as ezetimibe will decrease the
incidence of coronary artery disease.
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REPLY
In the letter by Drs. Radermecker and Scheen, it was noted that we
have not commented the potential of combining ezetimibe to
statins (1). The additional low-density lipoprotein (LDL) lowering
of combining cholesterol absorption inhibitors to statins is rela-
tively small, usually approximately 15%, for instance, for ezetimibe
or plant stanols. No clinical studies have been published defining
their additional reduction of coronary events during these treat-
ments, which seems to be true also for their monotherapy, even
though they are suitable for treatment of modestly increased LDL
cholesterol, and stanol ester management also provides the heart-
healthy fatty acids. Relatively low LDL cholesterol lowering either in
mono- or in combination with statin treatment certainly requires
randomized large-enough study populations treated for relatively long
periods of time to record changes in heart events. In addition to
LDL cholesterol lowering, cholesterol absorption inhibitors lower
also plant sterol levels off or on statin treatment. Thus, they also
normalize statin-induced increase of plant sterols. The endarter-
ectomized patients treated with statin in our study had increased
serum plant sterol ratios to cholesterol, which appeared also to be
reflected in atheromatous plaques of carotid arteries (1). This
finding certainly rises a question as to whether the lowering of
serum plant sterols with cholesterol absorption inhibitors, e.g.,
ezetimibe or plant stanols, also could reduce plant sterol contents
in the plaques. However, it also raises the question of whether an
increase of serum plant sterols, e.g., during the consumption of
plant sterol-enriched functional foods, also could enhance their
concentrations in atheromatous plaques. Several studies have
shown that increased serum plant sterols, even their ratios to
cholesterol, are associated with enhanced coronary artery disease in
crossover or follow-up investigations (2). However, in the Scan-
dinavian Simvastatin Survival Study, no association was found in
the control group between the five-year coronary events and
baseline plant sterol concentrations or ratios to cholesterol (2). In
the respective simvastatin treatment group, coronary events were
reduced significantly in the low absorber but unchanged in the
high absorbers, suggesting that additional lowering of LDL
cholesterol is needed in the latter type of patients, e.g., by
combination with cholesterol malabsorption. Statin treatment
seems to improve endothelial function of carotid arteries despite
increasing serum plant sterols (3); however, vascular function was
unaffected with phytosterol-enriched food when LDL cholesterol
was lowered and serum plant sterols were increased (4,5). Drs.
Radermecker and Scheen concluded that “elevated serum plant
sterols pose an increased cardiovascular risk,” but clinical heart
event reduction with their pharmacological lowering is still open.
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Danshen: A Popular
Chinese Cardiac Herbal Drug
The recently published document in JACC on complementary and
integrative medicine (1) left out one very important herbal drug,
danshen. Because it is believed to have properties of improving
microcirculation, increasing coronary blood flow, suppressing
thromboxane formation, inhibiting platelet adhesion and aggrega-
tion, and protecting against myocardial ischemia (2), it is used
either alone or in combination with other herbal ingredients for
patients with coronary artery disease (CAD), in both China and
other countries, including the U.S.
Conversely, danshen also interacts with warfarin by potentiating
its anticoagulant action (3). Because both warfarin usage and CAD
are so common in everyday cardiologic practice, the possibility of
the interaction between warfarin and danshen should be kept in
mind when excessive bleeding or unexpected prolongation of the
prothrombin time or international normalized ratio is encountered
in any patient on warfarin who has otherwise been under good
anticoagulant control. Because danshen is a common compound of
many cardiotonic herbal preparations, patients oftentimes may not
be aware that they are actually taking it. Furthermore, danshen can
be administered not only as an oral tablet but also in a nebulizer
(4). It has even been incorporated into some Chinese-brand
cigarettes (5), so that many cigarette smokers may not even be
aware of its presence.
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Complementary Medicine Has
No Place in Cardiovascular Medicine
The recent American College of Cardiology Foundation (ACCF)
Complementary Medicine Expert Consensus Document—
“Integrating Complementary Medicine Into Cardiovascular Med-
icine (1)”—presents problems for science-based physicians who
demand evidence-based medicine. Complementary medicine im-
plies that alternative medicine modalities are performed as an
adjunct to Western medicine. There is, however, no place for
unproven, unscientific (alternative) medicine in cardiovascular
medicine. Alternative medicine practitioners attempt to skirt the
unscientific nature of their unproven therapies by adding some
therapies that have always been considered conventional—exercise,
diets, physical therapy modalities, and relaxation prescriptions.
The Institute of Medicine (IOM) report (2) referred to in the
ACCF Document argues that the true complementary and alter-
native medicine practices (chiropractic, acupuncture, naturopathy,
homeopathy, and no doubt hundreds more) are rooted in forms of
evidence and logic other than those used in biomedical sciences. I
(3) and others have suggested that this constitutes the “free-ride”
of alternative medicine.
The ACCF document points out the deficiencies and lack of
evidence for most dietary supplements and herbs. I can think of
little if any place for herbs and supplements in modern cardiovas-
cular medicine. Today, we use digoxin, not the foxglove. Sampson
(4), in his discussion of herbal remedies and basically all alternative
remedies, suggests that they “are generally less effective or ineffec-
tive, and randomized clinical trials of these remedies measure
mostly subjective symptoms. . . . Inconsistent outcome from stud-
ies of alternative treatments seem to be the norm.”
The ACCF document alludes to the problems related to
chelation therapy, but it fails to criticize the launching of still
another expensive trial of that repeatedly disproved therapy.
Sampson suggests that, as scientists, we will not go astray by
supporting a medicine based on evidence that has passed through
the sieve of plausibility and that is consistent with basic sciences,
other applied sciences, and history—all molded by wisdom and
common sense.
The most glaring deficiency of the ACCF report is in the
lengthy section on acupuncture, which suggests that there is
evidence of value and potential indications for this alternative
therapy. A recent review by Atwood (5) claims that “investigations
of acupuncture to date have not demonstrated effects on the natural
history of any disease.” I know of no proven value for acupuncture
1498 Correspondence JACC Vol. 47, No. 7, 2006
April 4, 2006:1487–501
